Aligos Therapeutics, Inc. (NASDAQ:ALGS) Given Consensus Rating of “Moderate Buy” by Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $38.50.

A number of research firms have recently issued reports on ALGS. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Thursday, March 26th.

Aligos Therapeutics Price Performance

NASDAQ ALGS traded down $0.15 during mid-day trading on Friday, hitting $6.62. The stock had a trading volume of 109,331 shares, compared to its average volume of 279,756. The firm’s 50 day moving average is $5.70 and its 200 day moving average is $7.03. The stock has a market capitalization of $40.98 million, a price-to-earnings ratio of -0.76 and a beta of 2.26. Aligos Therapeutics has a twelve month low of $4.80 and a twelve month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, topping the consensus estimate of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The business had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million. As a group, equities research analysts expect that Aligos Therapeutics will post -7.47 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds have recently modified their holdings of ALGS. Bank of America Corp DE increased its holdings in shares of Aligos Therapeutics by 1,652.8% in the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after acquiring an additional 216,646 shares during the period. SummitTX Capital L.P. lifted its holdings in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after purchasing an additional 9,375 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after acquiring an additional 15,006 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $215,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.